(Q33397302)

26 July 2017

title

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

1 reference

Todd A Fehniger

1

0 references

David D. Hurd

8

object named as

David D Hurd

1 reference

26 July 2017

14

Nancy L Bartlett

1 reference

26 July 2017

6

Kristie A Blum

1 reference

26 July 2017

5

Amanda F Cashen

1 reference

26 July 2017

3

Kathryn Trinkaus

1 reference

26 July 2017

4

Marilyn J Siegel

1 reference

26 July 2017

Sarah Larson

2

1 reference

26 July 2017

Timothy S Fenske

7

1 reference

26 July 2017

Andre Goy

9

1 reference

26 July 2017

Stephanie E Schneider

10

1 reference

26 July 2017

Catherine R Keppel

11

1 reference

26 July 2017

Nina D Wagner-Johnston

12

1 reference

26 July 2017

Kenneth R Carson

13

1 reference

26 July 2017

language of work or name

English

0 references

publication date

21 September 2011

1 reference

26 July 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

26 July 2017

volume

118

1 reference

26 July 2017

issue

19

1 reference

26 July 2017

page(s)

5119-5125

1 reference

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Recent advances of IMiDs in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Mechanism of action of lenalidomide in hematological malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Drug development for recurrent and refractory classical Hodgkin lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Salvage regimens for Hodgkin lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Modern treatment of Hodgkin lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Lenalidomide for the treatment of B-cell malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Immunobiology and pathophysiology of Hodgkin lymphomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Revised response criteria for malignant lymphoma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3217400

10.1182/BLOOD-2011-07-362475

10 December 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference

26 July 2017

1 reference